Unmet needs of patients with narcolepsy: Perspectives on emerging treatment options

Nature and Science of Sleep

Volumn 7, Issue , 2015, Pages 51-61

  Wozniak, Dariusz R ^a   Quinnell, Timothy G ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Cataplexy; GABA B agonists; H3 antagonist; Hypocretin; Immunotherapy

Indexed keywords

EID: 84951905259     PISSN: None     EISSN: 11791608     Source Type: Journal    
DOI: 10.2147/NSS.S56077     Document Type: Review

References (116)

1. Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9-18.
2. Frauscher B, Ehrmann L, Mitterling T, et al. Delayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the innsbruck narcolepsy cohort. J Clin Sleep Med. 2013;9(8):805-812.
3. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
4. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18(2):78-105.
5. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499-511.
6. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58(12):1826-1833.
7. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502-507.
8. Dodel R, Peter H, Spottke A, et al. Health-related quality of life in patients with narcolepsy. Sleep Med. 2007;8:733-741.
9. Ingravallo F, Gnucci V, Pizza F, et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012;13:1293-1300.
10. Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086-1093.
11. Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 2009;5(3):240-245.
12. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep. 1994;17(8 Suppl):S45-S49.
13. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10(1):75-81.
14. Philip P, Sagaspe P, Lagarde E, et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med. 2010;11:973-979.
15. Nishino S, Kotorii N. Overview of management of narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorphy MJ, editors. Narcolepsy: A Clinical Guide. New York: Springer; 2010:251-265.
16. Morgenthaler TI, Kapur VK, Brown T, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-1711.
17. Prinzmetal M, Bloomberg W. The use of Benzedrine for the treatment of narcolepsy. JAMA. 1935;105(25):2051-2054.
18. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14(2):123-142.
19. Guilleminault C. Amphetamines and narcolepsy: use of the Stanford database. Sleep. 1993;16(3):199-201.
20. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739-752.
21. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep. 1991;14(3):218-220.
22. Billiard M, Dauvilliers Y, Dolenc-Grošelj L, Lammers GJ, Mayer G, Sonka K. Management of narcolepsy in adults. In: Gilhus NE, Barnes M, Brainin M, editors. European Handbook of Neurological Management. Vol 1. 2nd ed. Oxford: Blackwell Publishing; 2011:513-538.
23. Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy - clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10(7):386-395.
24. Guilleminault C, Aftab FA, Karadeniz D, Philip P, Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol. 2000;7(4):381-384.
25. Izzi F, Placidi F, Marciani MG, et al. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases. Sleep Med. 2009;10(1):153-154.
26. Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011;29(3):319-332.
27. McDonnell K. Narcolepsy patient community prepares to share life impacts, treatment perspectives with FDA regulators [press release]. Worcester, MA: Wake Up Narcolepsy, Inc.; 2013 [September 19]. Available from: http://www.wakeupnarcolepsy.org/press-releasenarcolepsy-patient-community-prepares-share-life-impacts-treatment-perspectives-fda-regulators. Accessed March 20, 2015.
28. Shneerson JM, Dauvilliers YA, Plazzi G, Myers AJ, Garcia-Borreguero D. The impact of narcolepsy and its treatment - a European study. Eur Neurol Rev. 2008;3(2):105-108.
29. Thorpy M, Zhao CG, Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med. 2013;14(4):367-376.
30. Hasegawa E, Yanagisawa M, Sakurai T, Mieda M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest. 2014;124(2):604-616.
31. Bourgin P, Huitrón-Résendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci. 2000;20(20):7760-7765.
32. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A. 2001;98(17):9965-9970.
33. Xi MC, Morales FR, Chase MH. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001;901(1-2):259-264.
34. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101(13):4649-4654.
35. Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci. 2014;8:57.
36. Mishima K, Fujiki N, Yoshida Y, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep. 2008;31(8):1119-1126.
37. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953-959.
38. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online. 2000;3(1):23-28.
39. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9 Suppl 3:S5.
40. Dhuria SV, Hanson LR, Frey WH 2nd. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther. 2009;328(1): 312-320.
41. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239-14247.
42. Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin a (hypocretin-1). Brain 2008;131(Pt 10): 2734-2741.
43. Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941-946.
44. Lammers GJ. Intranasal hypocretin-1: making sense of scents? Sleep Med. 2011;12(10):939-940.
45. Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8-13.
46. Sun H, Kennedy WP, Wilbraham D. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259-267.
47. Boss C. Orexin receptor antagonists - a patent review (2010 to August 2014). Expert Opin Ther Pat. 2014;24(12):1367-1381.
48. Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human orexin-1 and orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry. 2013;52(46):8246-8260.
49. Arias-Carrión O, Murillo-Rodríguez E. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS One. 2014;9(4):e95342.
50. Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci. 2014;8:113.
51. Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci. 2008;28: 1382-1393.
52. Liu M, Blanco-Centurion C, Konadhode R, et al. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci. 2011;31:6028-6040.
53. Blanco-Centurion C, Liu M, Konadhode R, Pelluru D, Shiromani PJ. Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. Sleep. 2013;36(1):31-40.
54. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88(3):1183-1241.
55. Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther. 2011;336(1):17-23.
56. Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep. 2009;32(2):175-180.
57. De la Herrán-Arita AK, García-García F. Current and emerging options for the drug treatment of narcolepsy. Drugs. 2013;73(16): 1771-1781.
58. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713-721.
59. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30(1):74-83.
60. Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55-60.
61. Dauvilliers Y, Bassetti C, Lammers GJ, et al; HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068-1075.
62. Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci. 2003;18(10):2722-2730.
63. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric acid, and baclofen on EEG activity and sleep regulation. J Neurosci. 2010;30(42):14194-14204.
64. Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol. 2009;41(1):9-16.
65. Black SW, Morairty SR, Chen TM, et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci. 2014; 34(19):6485-6494.
66. Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug Healthc Patient Saf. 2014;6:69-76.
67. Kolesnick RN, Gershengorn MC. Thyrotropin-releasing hormone and the pituitary. New insights into the mechanisms of stimulated secretion and clinical usage. Am J Med. 1985;79(6):729-739.
68. Nillni EA. Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol. 2010;31(2):134-156.
69. Sun Y, Zupan B, Raaka BM, Toth M, Gershengorn MC. TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology. 2009;34(6): 1601-1608.
70. Van den Bergh P, Octave JN, Lechan RM. Muscle denervation increases thyrotropin-releasing hormone (TRH) biosynthesis in the rat medullary raphe. Brain Res. 1991;566(1-2):219-224.
71. Eto K, Kim SK, Nabekura J, Ishibashi H. Taltirelin, a thyrotropin-releasing hormone analog, alleviates mechanical allodynia through activation of descending monoaminergic neurons in persistent inflammatory pain. Brain Res. 2011;1414:50-57.
72. Horita A. An update on the CNS actions of TRH and its analogs. Life Sci. 1998;62:1443-1448.
73. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res. 2006;153:209-235.
74. Daimon CM, Chirdon P, Maudsley S, Martin B. The role of thyrotropin releasing hormone in aging and neurodegenerative diseases. Am J Alzheimers Dis (Columbia). 2013;1(1).
75. Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma. 1995;12(3):235-243.
76. Kelly JA, Boyle NT, Cole N, et al. First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. Neuropharmacology. 2015;89:193-203.
77. Kamath J, Feinn R, Winokur A. Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. Support Care Cancer. 2012;20(8):1745-1753.
78. Sah N, Rajput SK, Singh JN, et al. L-pGlu-(2-propyl)-L-His-L-ProNH2 attenuates 4-aminopyridine-induced epileptiform activity and sodium current: a possible action of new thyrotropin-releasing hormone analog for its anticonvulsant potential. Neuroscience. 2011;199:74-85.
79. Kato Z, Okuda M, Okumura Y, et al. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy. J Child Neurol. 2009;24(8):1010-1012.
80. Broberger C, McCormick DA. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci. 2005;25(7):1664-1673.
81. Khomane KS, Meena CL, Jain R, Bansal AK. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat. 2011;21(11):1673-1691.
82. Redding TW, Schally AV. On the half life of thyrotropin-releasing hormone in rats. Neuroendocrinology. 1972;9(4):250-256.
83. Monga V, Meena C, Rajput S, et al. Synthesis, receptor binding, and CNS pharmacological studies of new thyrotropin-releasing hormone (TRH) analogues. ChemMedChem. 2011;6(3):531-543.
84. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997; 17(16):6401-6408.
85. Riehl J, Honda K, Kwan M, Hong J, Mignot E, Nishino S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology. 2000;23(1):34-45.
86. Monga V, Meena CL, Kaur N, Jain R. Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem. 2008;15(26):2718-2733.
87. Thirunarayanan N, Nir EA, Raaka BM, Gershengorn MC. Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. Neuropsychopharmacology. 2013;38(6):950-956.
88. Thirunarayanan N, Raaka BM, Gershengorn MC. Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor. Front Endocrinol (Lausanne). 2012;3:120.
89. Asai H, Asahi T, Yamamura M, Yamauchi-Kohno R, Saito A. Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats. Pharmacol Biochem Behav. 2005;82(4):646-651.
90. Hara J, Gerashchenko D, Wisor JP, Sakurai T, Xie X, Kilduff TS. Thyrotropin-releasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons. J Neurosci. 2009;29(12): 3705-3714.
91. González JA, Horjales-Araujo E, Fugger L, Broberger C, Burdakov D. Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone. J Physiol. 2009;587(Pt 6):1179-1186.
92. Parmentier R, Kolbaev S, Klyuch BP, et al. Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci. 2009;29(14):4471-4483.
93. Zhang X, van den Pol AN. Thyrotropin-releasing hormone (TRH) inhibits melanin-concentrating hormone neurons: implications for TRH-mediated anorexic and arousal actions. J Neurosci. 2012;32(9): 3032-3043.
94. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41:708-711.
95. Hor H, Kutalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010;42:786-789.
96. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120:713-719.
97. Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokynaga K, Honda M. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep. 2010;33:875-878.
98. Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33:869-874.
99. Lim AS, Scammell TE. The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy? Sleep. 2010;33(7):857-858.
100. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70:410-417.
101. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012;7:e33723.
102. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 2013;14:867-871.
103. Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014;50: 1-11.
104. Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255(12):1900-1903.
105. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549-1554.
106. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins shortly after narcolepsy onset. Ann Neurol. 2004;56:905-908.
107. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol. 2006;60(1):153.
108. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347-348.
109. Zuberi SM, Mignot E, Ling L, et al. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res. 2004; 13(Suppl 1):828. Abstract.
110. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol. 2005;58(3):489-490.
111. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-474.
112. Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res. 2012;21(4):479-480.
113. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol. 2010;22(5):609-615.
114. Hasan S, Pradervand S, Ahnaou A, Drinkenburg W, Tafti M, Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology. 2009;34(7): 1625-1640.
115. Amsterdam JD, Brunswick DJ, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(7-8):1333-1338.
116. Black J, Swick T, Feldman N, et al. Efficacy and safety of oral ADX-N05 for the treatment of excessive daytime sleepiness in adults with narcolepsy: results of a randomized, double-blind, placebo-controlled trial [abstract]. Presented at: 28th Annual Meeting of the Associated Professional Sleep Societies (SLEEP); May 31-June 4, 2014; Minneapolis, MN. Abstract LBA4.